Literature DB >> 12433110

Determination of the norepinephrine level by high-performance liquid chromatography to assess the protective effect of MAO-B inhibitors against DSP-4 toxicity.

Diana Haberle1, Kálmán Magyar, Eva Szöko.   

Abstract

Liquid chromatography (LC) combined with electrochemical detection (EC) is suitable for measuring oxidizable biogenic amine levels in small samples of brain tissue. The norepinephrine (NE) content in mouse hippocampus after treatment with various monoamine oxidase-B enzyme (MAO-B) inhibitors ([-]-deprenyl, [+]-rasagiline, and the noradrenergic neurotoxin N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine [DSP-4]) is determined using an LC-EC method. Treatment with a single intraperitoneal dose of (-)-deprenyl (selegiline) before DSP-4 administration markedly reduces the NE depleting effect of the toxin, and (+)-rasagiline does not significantly modify the NE level decreased by the neurotoxin. The MAO-B inhibitory potency of (-)-deprenyl and (+)-rasagiline is also evaluated. Significantly reduced MAO-B enzyme activity in mouse brain and liver is measured 6 h after treatment with their single dose. (+)-Rasagiline is found to be a more potent MAO-B inhibitor than (-)-deprenyl.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433110     DOI: 10.1093/chromsci/40.9.495

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  3 in total

Review 1.  DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action.

Authors:  Svante B Ross; Carina Stenfors
Journal:  Neurotox Res       Date:  2014-06-26       Impact factor: 3.911

2.  Bio-analytical method development and validation of Rasagiline by high performance liquid chromatography tandem mass spectrometry detection and its application to pharmacokinetic study.

Authors:  Ravi Kumar Konda; Babu Rao Chandu; B R Challa; Chandrasekhar B Kothapalli
Journal:  J Pharm Anal       Date:  2012-05-11

3.  Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis.

Authors:  Carmen Herranz; Francesca Mateo; Alexandra Baiges; Gorka Ruiz de Garibay; Alexandra Junza; Simon R Johnson; Suzanne Miller; Nadia García; Jordi Capellades; Antonio Gómez; August Vidal; Luis Palomero; Roderic Espín; Ana I Extremera; Eline Blommaert; Eva Revilla-López; Berta Saez; Susana Gómez-Ollés; Julio Ancochea; Claudia Valenzuela; Tamara Alonso; Piedad Ussetti; Rosalía Laporta; Antoni Xaubet; José A Rodríguez-Portal; Ana Montes-Worboys; Carlos Machahua; Jaume Bordas; Javier A Menendez; Josep M Cruzado; Roser Guiteras; Christophe Bontoux; Concettina La Motta; Aleix Noguera-Castells; Mario Mancino; Enrique Lastra; Raúl Rigo-Bonnin; Jose C Perales; Francesc Viñals; Alvaro Lahiguera; Xiaohu Zhang; Daniel Cuadras; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Harilaos Filippakis; Razq Hakem; Chiara Gorrini; Marc Ferrer; Aslihan Ugun-Klusek; Ellen Billett; Elżbieta Radzikowska; Álvaro Casanova; María Molina-Molina; Antonio Roman; Oscar Yanes; Miquel A Pujana
Journal:  EMBO Mol Med       Date:  2021-08-11       Impact factor: 12.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.